BioNTech SE

BRSE:22UA Stock Report

Market Cap: CHF 24.5b

BioNTech Valuation

Is 22UA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 22UA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 22UA?

Key metric: As 22UA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 22UA. This is calculated by dividing 22UA's market cap by their current revenue.
What is 22UA's PS Ratio?
PS Ratio8.6x
Sales€3.04b
Market Cap€26.17b

Price to Sales Ratio vs Peers

How does 22UA's PS Ratio compare to its peers?

The above table shows the PS ratio for 22UA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.1x
MOLN Molecular Partners
28.4x57.9%CHF 170.7m
BSLN Basilea Pharmaceutica
3.3x5.9%CHF 498.8m
GALD Galderma Group
6x11.5%CHF 23.4b
KURN Kuros Biosciences
14.4xn/aCHF 759.0m
22UA BioNTech
8.6x2.8%CHF 27.3b

Price-To-Sales vs Peers: 22UA is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (13.1x).

Price to Sales Ratio vs Industry

How does 22UA's PS Ratio compare vs other companies in the European Biotechs Industry?

40 CompaniesPrice / SalesEstimated GrowthMarket Cap
22UA 8.6xIndustry Avg. 8.2xNo. of Companies40PS0816243240+
40 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 22UA is expensive based on its Price-To-Sales Ratio (8.6x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is 22UA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

22UA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.6x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: 22UA is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 22UA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 101.32
CHF 122.02
+20.4%
10.8%CHF 152.44CHF 107.31n/a19
Dec ’25CHF 107.28
CHF 120.62
+12.4%
9.6%CHF 152.54CHF 107.66n/a18
Nov ’25n/a
CHF 112.35
0%
17.1%CHF 148.58CHF 77.67n/a18
Oct ’25CHF 101.13
CHF 104.90
+3.7%
19.6%CHF 144.68CHF 71.91n/a18
Sep ’25CHF 74.97
CHF 93.38
+24.5%
20.4%CHF 146.44CHF 72.79n/a18
Aug ’25CHF 76.19
CHF 97.51
+28.0%
20.3%CHF 149.47CHF 78.74n/a18
Jul ’25CHF 73.23
CHF 99.23
+35.5%
20.2%CHF 152.93CHF 80.05n/a18
Jun ’25CHF 90.34
CHF 100.88
+11.7%
20.4%CHF 155.28CHF 81.46n/a18
May ’25CHF 80.78
CHF 104.37
+29.2%
20.7%CHF 154.20CHF 81.51n/a18
Apr ’25n/a
CHF 105.78
0%
23.6%CHF 168.60CHF 81.03n/a18
Mar ’25CHF 78.97
CHF 111.20
+40.8%
22.5%CHF 165.26CHF 86.95n/a17
Feb ’25CHF 82.57
CHF 109.46
+32.6%
22.4%CHF 161.50CHF 84.97n/a16
Jan ’25n/a
CHF 113.39
0%
21.0%CHF 158.94CHF 85.88n/a16
Dec ’24CHF 87.65
CHF 117.09
+33.6%
23.0%CHF 172.94CHF 86.18CHF 107.2817
Nov ’24n/a
CHF 126.54
0%
23.1%CHF 175.48CHF 92.43n/a17
Oct ’24n/a
CHF 133.80
0%
22.9%CHF 180.14CHF 90.81CHF 101.1316
Sep ’24n/a
CHF 136.90
0%
26.1%CHF 218.68CHF 87.10CHF 74.9717
Aug ’24n/a
CHF 141.05
0%
24.7%CHF 218.68CHF 94.81CHF 76.1917
Jul ’24n/a
CHF 148.65
0%
23.1%CHF 223.32CHF 96.82CHF 73.2316
Jun ’24n/a
CHF 146.01
0%
23.4%CHF 222.46CHF 96.45CHF 90.3417
May ’24n/a
CHF 159.77
0%
23.7%CHF 235.98CHF 114.71CHF 80.7817
Apr ’24n/a
CHF 168.27
0%
22.2%CHF 238.15CHF 119.64n/a16
Mar ’24n/a
CHF 191.64
0%
23.4%CHF 276.48CHF 131.37CHF 78.9715
Feb ’24n/a
CHF 192.61
0%
23.5%CHF 278.08CHF 132.58CHF 82.5715
Jan ’24n/a
CHF 198.61
0%
23.2%CHF 305.53CHF 141.84n/a15
Dec ’23n/a
CHF 200.71
0%
22.4%CHF 304.11CHF 141.90CHF 87.6516

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 12:44
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioNTech SE is covered by 29 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research